MedZora Article

Dr. Sameer Idris - Gastroenterology

The PROFILE trial, published in The Lancet Gastroenterology & Hepatology, has added new data to the conversation about how we start treatment for Crohn's disease. In the study, patients who were diagnosed within the past six months received a TNF‑alpha inhibitor (infliximab) right away, a strategy sometimes called "top‑down." The comparison group began with conventional medicines such as aminosalicylates or steroids and added biologic therapy only if symptoms persisted - the traditional "step‑up" approach.

The primary outcome was clinical remission at 52 weeks. Remission was defined as the absence of abdominal pain, diarrhea, and weight loss, together with normal blood markers of inflammation. According to the report, about 79 % of the top‑down group met this definition, while roughly 15 % of the step‑up group did so. The authors noted that the difference was statistically significant, meaning it is unlikely to be due to chance alone.

What does this mean for patients who have just received a Crohn's diagnosis? The data suggest that beginning treatment with a biologic drug early in the disease course may lead to faster and more frequent symptom control for many individuals. Early control of inflammation has been linked in other studies to a lower chance of developing strictures (narrowed sections of bowel) or fistulas (abnormal connections between organs). However, the PROFILE trial also reported that some participants experienced side‑effects typical of TNF‑alpha inhibitors, such as mild infusion reactions, respiratory infections, and rare serious infections. These risks need to be balanced against the potential benefit of early remission.

Why might clinicians consider a top‑down approach? Crohn's disease can be unpredictable. In some patients, inflammation progresses quickly and leads to irreversible damage that may ultimately require surgery. By suppressing the immune response early, the hope is to prevent that damage before it becomes entrenched. In the trial, the need for intestinal surgery over the two‑year follow‑up was lower in the early biologic group, though the absolute numbers were small and longer follow‑up will be needed to confirm this trend.

It is also worth noting that the study enrolled patients with moderate to severe disease activity at baseline, as measured by a disease activity index. Results may not apply in exactly the same way to people with very mild disease who feel well on dietary changes or low‑dose medication. In clinical practice, the decision to start a biologic early usually involves a detailed discussion about disease severity, personal preferences, and potential costs.

How should someone newly diagnosed with Crohn's think about these findings? Here are a few practical steps:

1. Ask about disease activity - Your gastroenterologist may use a scoring system, blood tests, imaging, or endoscopy to gauge how active the disease is. Understanding the baseline helps in weighing treatment options.

2. Discuss the pros and cons of early biologic therapy - Ask how biologics work, what monitoring will involve, and what side‑effects you might expect. Knowing the infection risk and the need for regular blood work can help you feel prepared.

3. Consider your lifestyle and preferences - Some patients prefer to avoid injections or infusions early on, while others value the possibility of quicker symptom relief. Your comfort with the treatment schedule matters.

4. Review insurance coverage - Biologic medicines can be expensive, and coverage varies. Your clinic's financial counselor can help you understand what is reimbursed and whether patient assistance programs are available.

5. Plan for follow‑up - If you start a biologic, you'll likely have lab tests every few months to check liver function, blood counts, and infection markers. You may also have repeat imaging or endoscopy after a year to see how the bowel has responded.

6. Stay alert for warning signs - Fever, persistent cough, unexplained skin rashes, or severe fatigue could signal infection. Contact your doctor promptly if these arise.

The PROFILE trial adds to a growing body of research that supports early aggressive therapy for certain patients with Crohn's disease. While the results are encouraging, they are not a one‑size‑fits‑all solution. Individual factors such as age, overall health, disease location, and personal goals all influence the best treatment plan.

If you have been diagnosed recently, consider scheduling a dedicated appointment to review the latest evidence, including the findings from PROFILE, and to explore whether a top‑down strategy aligns with your health objectives. Remember that treatment decisions are made together with your healthcare team, and you have the right to ask questions at every step.

This article provides general information and is not a substitute for personalized medical advice. Please consult your own clinician before making any changes to your treatment plan.